Clinical trial
A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
NCT05904093 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 18, 2024
- Completion date
- May 14, 2027
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
disease sickle cell anemia, hb-ss disease, hemoglobin s, sickle cell disease, sickle cell disorders